Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients

被引：13

作者：

Bellmunt, Joaquim ^{[1
]}

Fishman, Mayer ^{[2
]}

Eisen, Timothy ^{[3
]}

Quinn, David ^{[4
]}

机构：

[1] Univ Hosp Mar IMIM, RTICC, Barcelona 08003, Spain

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[3] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 0QQ, England

[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 06期

关键词：

elderly; multiple lines of therapy; patient adherence; quality of life; renal cell carcinoma; sorafenib; systemic therapy; watch and wait; KIDNEY CANCER; KINASE INHIBITORS; INTERFERON-ALPHA; OLDER PATIENTS; EFFICACY; THERAPY; SAFETY; HYPERTENSION; TEMSIROLIMUS; SUNITINIB;

D O I：

10.1586/ERA.10.68

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The incidence of renal cell carcinoma is increasing globally. Targeted agents offer treatment options that were not available less than a decade ago. However, it is important to carefully select therapy for each individual patient, weighing both the drug efficacy and tolerability profile and patient-related factors, such as adherence, age and comorbidities. Based on our clinical experience in treating patients with renal cell carcinoma, this article offers our opinions on factors that characterize patients for whom sorafenib may serve as a viable first-line therapeutic option.

引用

页码：825 / 835

页数：11

共 75 条

[1] Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors [J].